Last reviewed · How we verify
FDC
FDC is a cardiovascular investigational drug developed by a Spanish research foundation, but its specific mechanism of action is not publicly disclosed.
At a glance
| Generic name | FDC |
|---|---|
| Sponsor | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Without access to detailed clinical trial data or published mechanisms, the precise molecular target and pharmacological action cannot be reliably determined. The drug is in Phase 3 development under a cardiovascular research organization, suggesting a focus on heart disease or related conditions, but the exact mechanism remains proprietary or undisclosed.
Approved indications
Common side effects
Key clinical trials
- A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy (PHASE2, PHASE3)
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma (PHASE2)
- A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (PHASE2)
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (PHASE3)
- Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (PHASE2)
- Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FDC CI brief — competitive landscape report
- FDC updates RSS · CI watch RSS
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III portfolio CI